Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996–3018. Socinski, 2007, Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 132, 277S, 10.1378/chest.07-1381 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 Scagliotti, 2009, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies, Oncologist, 14, 253, 10.1634/theoncologist.2008-0232 Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5 Scagliotti, 2005, Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial, Clin Cancer Res, 11, 690, 10.1158/1078-0432.690.11.2 Zinner, 2005, Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer, Cancer, 104, 2449, 10.1002/cncr.21480 Grønberg, 2009, Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 27, 3217, 10.1200/JCO.2008.20.9114 Patel, 2009, Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer, J Clin Oncol, 27, 3284, 10.1200/JCO.2008.20.8181 Calvert, 1989, Carboplatin dosage: prospective evaluation of a simple formula based on renal function, J Clin Oncol, 7, 1748, 10.1200/JCO.1989.7.11.1748 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 475, 10.2307/2281868 Orlando M, Lee JS, Yang C, Simms L, Park K. Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC). Poster presented at: annual meeting of the American Society of Clinical Oncology 29 May to 2 June 2009, Florida. Ohe, 2008, Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer, Clin Cancer Res, 14, 4206, 10.1158/1078-0432.CCR-07-5143